When: After asymmetric trim triggered - close above $68.52 on >20M shares with MACD re-acceleration OR pullback to $63.00-$63.50 zone

Then: Add back the 25% trimmed position

HOLD with 1-2% defensive position sizing; willing to add to 3-4% on confirmed breakout above 68.52 on 20M+ volume with positive MACD cross and RSI above 65, or on pullback to 63-63.50 zone

• Volume collapsed approximately 83% from 32.97 million shares on August 3rd breakout to 5.5 million currently, with no follow-through days with expanding volume within 1-2 weeks
• Forward PE of 10.15x appears optically cheap against sector at 17-20x but market is rationally pricing in Eliquis and Revlimid erosion representing tens of billions in revenue exposure through 2028
• Revenue has been flat to down for four consecutive years
• Balance sheet carries 2.0x debt-to-equity with negative tangible book value and $47 billion in total debt
• ZENBEXUS is one drug in one indication competing against established players like Darzalex-based combinations, and J&J partnership means BMY does not capture full economics
• Drug pricing risk is concentrated and severe: Eliquis is one of the most expensive drugs in Medicare and the single highest-profile drug pricing target in Washington
• Break below 50 SMA at 61.55 represents approximately 7.5% downside from current price of 66.58
• Conservative analyst will not add until breakout above 68.52 on 20M+ volume with MACD flip positive and RSI back above 65, or pullback to 63-63.50 zone improves risk-reward
• Beta of 0.225; target entry zone of 63-63.50 improves asymmetry materially
• Patent cliff concerns include Eliquis and Revlimid erosion; Cytokinetics Acacia Phase 3 win in non-obstructive HCM represents competitive risk; terminated Cellares partnership and unresolved Breyanzi manufacturing question represent additional independent risks
• Target entry for upside is approximately 72 (fair value) vs current 66.58 (~8% upside) but downside risk of 7.5% to 50 SMA and more on real break does not pencil out at current prices

→ vs aggressive: Volume collapse from 32.97M to 5.5M shares (83% decline) contradicts accumulation thesis; no follow-through days with expanding volume within 1-2 weeks of breakout; institutional bid is not continuing

→ vs aggressive: Poking a hole in one bear argument (competitive mechanism) does not neutralize four or five independent bear arguments including patent cliff, Cytokinetics Acacia Phase 3 competition, terminated Cellares partnership, and unresolved Breyanzi manufacturing

→ vs aggressive: Forward PE of 10.15x being 'optically cheap' ignores why the multiple is compressed: market is rationally pricing Eliquis/Revlimid erosion, 4 years of flat-to-declining revenue, leverage, and J&J partnership dependency

→ vs aggressive: Drug pricing tail risk is not 'temporally distant and unmodeled'—Eliquis is the single highest-profile drug pricing target in Washington and any MFN executive order would hit revenue 'with the force of a freight train'; Polymarket absence of contract does not mean risk is gone

→ vs aggressive: 2-3% position with beta of 0.225 combined with 7.5% downside to 50 SMA creates concentrated idiosyncratic risk that violates prudent diversification; 1-2% defensive sizing is appropriate not timid

→ vs aggressive: Waiting for confirmation is not 'missing the move'—breakout above 68.52 on 20M+ volume with positive MACD and RSI above 65 will still offer plenty of upside; 5% upside to 70 and 8% to fair value of 72 does not offset 7.5% downside to 50 SMA at current prices

Hold with explicit add triggers: pullback to $63-63.50 or breakout above $68.52 on volume above 20M

• Hold is the right base case with 1-2% position appropriate given mediocre risk-reward at current prices
• Current price $66.58 has 7.5% downside to 50 SMA but only 5-8% upside to resistance, not paying to take the risk
• Aggressive is selectively underweighting multiple independent bear risk vectors (patent cliff, Cytokinetics Acacia data, Cellares termination, Breyanzi manufacturing)
• Conservative underweights forward PE argument—BMY has 44% forward earnings expansion, not a company in secular decline
• ZENBEXUS first-in-class approval based on MRD-negative complete response data is a meaningful regulatory and clinical signal
• Volume argument is confirmation bias—the 83% volume collapse from 32.97M shares to 5.5M shares is not textbook healthy consolidation
• Drug pricing risk is real and structurally present but temporally distant and not currently priced
• Beta of 0.225 does not protect from idiosyncratic drawdowns at 3-4% concentration
• Dividend yield of 3.76% compensates while waiting for setup to resolve

→ vs aggressive: The 83% volume collapse from 32.97M shares to 5.5M shares at the 52-week high after a 20%+ run-up is not 'textbook healthy consolidation'—it may be exhaustion rather than accumulation

→ vs aggressive: Cannot neutralize five bear arguments by poking a hole in one—the risk surface is broader than selective technical analysis suggests

→ vs aggressive: Position sizing at 2-3% scaling to 3-4% is too aggressive given live patent cliff and unmodeled drug pricing risk with low beta providing no idiosyncratic protection

→ vs conservative: Forward PE of 10.15 with 44% forward earnings expansion deserves more weight—the market is pricing in the patent cliff but not yet the new product cycle

→ vs conservative: Dismissal of ZENBEXUS first-in-class approval based on MRD-negative complete response data underweights a meaningful regulatory and clinical signal against the 'cannot innovate' bear case

→ vs conservative: The 'market isn't stupid' framing ignores that cheap multiples persist when markets are slow to recognize structural change in companies that have absorbed major write-downs